Zobrazeno 1 - 10 of 21 pro vyhledávání: '"I C, Quirt"'
2
Phase II trial of 10-EDAM in advanced soft tissue sarcoma
Autor: Audley Bodurtha, Eric L. Eisenhauer, G. Boos, M. Knowling, Vivien H.C. Bramwell, I. C. Quirt
Publikováno v: Annals of Oncology. 5:766-768
BACKGROUND Inoperable locally recurrent soft tissue sarcomas (STS) are incurable with chemotherapy. Therefore the National Cancer Institute of Canada Clinical Trials Group are performing phase II studies in an attempt to find better drugs. PATIENTS A
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e0e9e97f5487522a2c2d4518e72ac98c
https://doi.org/10.1093/oxfordjournals.annonc.a058985
Zobrazit plný text záznamu
3
Sentinel lymph-node biopsy after previous wide local excision for melanoma
Autor: D R, McCready, D M, Ghazarian, M S, Hershkop, J A, Walker, U, Ambus, I C, Quirt
Publikováno v: Canadian journal of surgery. Journal canadien de chirurgie. 44(6)
To document experience with sentinel lymph-node biopsy in patients who have already undergone a wide local excision for melanoma because in many centres previous wide excision has been a contraindication for sentinel lymph-node biopsy.A prospective c
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f7c05a139c79a32726423a920ff64b5b
https://pubmed.ncbi.nlm.nih.gov/11764876
Zobrazit plný text záznamu
4
Acute Myeloblastic Leukemia: Management with High-Dose Cytosine Arabinoside, Daunorubicin and Marrow Transplantation; Malignancy; Current Clinical Practice
Autor: J. E., Curtis, Y., Hao, H. A., Messner, J. H., Lipton, R., Lowsky, I. C., Quirt, J. F. G., Sturgeon, B., Zanke, A., Keating, M. D., Minden
Publikováno v: Hematology (Amsterdam, Netherlands). 5(3)
Combination high-dose cytosine arabinoside (ARA-C) and daunorubicin (DNR) for primary remission induction of patients with acute myeloblastic leukemia (AML) was evaluated in a single institution study. Patients aged 55 or less with an HLA-sibling rec
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::31d899120b58218e83df24dd7713471e
https://pubmed.ncbi.nlm.nih.gov/11399613
Zobrazit plný text záznamu
5
Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial
Autor: I. C. Quirt, Frank L. Graham, Lorne E. Rotstein, Denis Bailey, N J Lassam, Steven Gallinger, D. Cappe, Christina L. Addison, Sophie Dessureault, Yonghong Wan, R C Moen, M. Krajden, Jack Gauldie, A K Stewart
Publikováno v: Gene therapy. 6(3)
We conducted a phase 1 trial of direct injection of an E1, E3-deleted adenovirus encoding interleukin-2 (AdCAIL-2) into subcutaneous deposits of melanoma or breast cancer. Twenty-three patients were injected at seven dose levels (10(7)-10(10) p.f.u).
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b28f0f7327bd3223bea6420128ca02b7
https://pubmed.ncbi.nlm.nih.gov/10435085
Zobrazit plný text záznamu
8
A phase II study of weekly edatrexate (10-EDAM) in metastatic melanoma. A National Cancer Institute of Canada Clinical Trials Group study
Autor: S, Verma, I C, Quirt, E A, Eisenhauer, N A, Iscoe, V J, Young, A J, Bodurtha, J, Davidson
Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 4(3)
Phase I and II clinical trials have demonstrated acceptable toxicity and promising activity of Edatrexate (10-EDAM). The objective of this multicentre phase II study was to determine the efficacy and toxicity of this agent in patients with metastatic
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1f575879fa4272c86d89e556324b7855
https://pubmed.ncbi.nlm.nih.gov/8471559
Zobrazit plný text záznamu
10
A phase II study of weekly Edatrexate (10-EDAM) in metastatic melanoma
Autor: Elizabeth Eisenhauer, Shailendra Verma, Neill Iscoe, Audley Bodurtha, I. C. Quirt, V. J. Young, J. Davidson
Publikováno v: Annals of Oncology. 4:254-255
Summary Background Phase I and II clinical trials have demonstrated acceptable toxicity and promising activity of Edatrexate (10-EDAM). The objective of this multicentre phase II study was to determine the efficacy and toxicity of this agent in patie
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3a1ba6a246c1bb91f59abfee132e00f0
https://doi.org/10.1093/oxfordjournals.annonc.a058467
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje